Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joo Jang

Nurse Practitioner, Family Leonia, NJ Nurse Practitioner

NPI 1295349058 CMS profile 11086610

388 Broad Ave, Leonia, NJ 07605

Open in the dashboard

General payments

$1,543

70 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joo Jang of Leonia, NJ is reported in the CMS Open Payments database as having received $1,543 across 70 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $369 15
2024 General $646 19
2023 General $147 9
2022 General $307 22
2021 General $74 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joo Jang
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Joo Jang were reported at $369. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Joo Jang Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $74 $124 $35–$379 $132
2022 $307 $141 $44–$430 $149
2023 $147 $154 $49–$476 $160
2024 $646 $165 $51–$504 $164
2025 $369 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $446 8 payments
  2. AstraZeneca Pharmaceuticals LP $204 6 payments
  3. Novo Nordisk Inc $179 11 payments
  4. Lilly USA, LLC $155 9 payments
  5. IBSA Pharma Inc. $75 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $66 4 payments
  7. Nestle HealthCare Nutrition Inc. $57 4 payments
  8. Otsuka America Pharmaceutical, Inc. $38 2 payments
  9. Scilex Pharmaceuticals Inc. $34 2 payments
  10. Aimmune Therapeutics, Inc. $32 2 payments
  11. Other $257 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,482 65 payments
  2. Education $62 5 payments
Products named General payments · program years 2021–2025
  1. EVENITY $429 7 payments
  2. FARXIGA $179 4 payments
  3. ZENPEP $90 6 payments
  4. Tirosint $75 5 payments
  5. Licart $75 5 payments
  6. MOUNJARO $73 4 payments
  7. RYBELSUS $68 4 payments
  8. Ozempic $68 4 payments
  9. TRADJENTA $66 4 payments
  10. JARDIANCE $66 4 payments
  11. Other $763 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 188 drugs

Part D claims

27,030

Median for Nurse Practitioner: 389

Drug cost

$6,331,968

Median for Nurse Practitioner: $21,885

Branded share of claims

34.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 696 $1,387,890
Zenpep Lipase/Protease/Amylase Brand 323 $783,628
Vascepa Icosapent Ethyl Brand 1,931 $714,823
Ztlido Lidocaine Brand 490 $338,763
Prolia Denosumab Brand 208 $338,730
Lidocaine Generic 1,362 $254,041
Farxiga Dapagliflozin Propanediol Brand 266 $185,987
Restasis Cyclosporine Brand 237 $182,649
Jardiance Empagliflozin Brand 255 $181,232
Linzess Linaclotide Brand 313 $170,237

The 10 drugs with the highest cost, of 188 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$58,796

Of which drugs: $2,637

Medicare patients

267

Average age 80

Services billed

1,065

179 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 52%
Diabetes 49%
Depression 40%
Arthritis 40%
Osteoporosis 38%
Alzheimer's or dementia 32%
Chronic kidney disease 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 32 32 $2,618

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $255
$255 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $155
$155 266 —
MOUNJARO
  • Lilly USA, LLC $26
$26 38 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $20
$20 — —
JARDIANCE
  • Lilly USA, LLC $19
$19 255 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

70 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record